CD19 as a Target in the Treatment of DLBCL

A review of the criteria that help hematologist-oncologists appropriately manage patients with diffuse large B-cell lymphoma.

A discussion of standard frontline treatment approaches and considerations for utilizing maintenance therapy for patients with germinal center B-cell and activated B-cell subtypes of diffuse large B-cell lymphoma.

The differences between frontline treatment strategies for early stage vs double- or triple-hit diffuse large B-cell lymphoma.

Debates regarding the proper timing for repeat scans, interval CT testing, and surveillance imaging on patients with diffuse large B-cell lymphoma following frontline therapy.

Variables that impact a patient with diffuse large B-cell lymphoma, and prognosis and strategies for counseling patients on goals of therapy.

The rationale for sequencing therapy with CD19-targeted agents when managing patients with various subtypes of diffuse large B-cell lymphoma.

Recommendations for approaching patients with relapsed/refractory diffuse large B-cell lymphoma with newer targeted treatment approaches as frontline therapy vs referral for transplant.

Implications for treating unfit patients with relapsed/refractory diffuse large B-cell lymphoma with chemotherapy or the combination of tafasitamab and lenalidomide based on patient characteristics and the L-MIND trial.

Drs John M. Burke and Marin F. Xavier consider the potential utilization of tafasitamab plus lenalidomide plus R-CHOP chemotherapy vs R-CHOP chemotherapy alone as relapsed/refractory diffuse large B-cell lymphoma treatment.

An overview of potential strategies being explored to improve frontline therapy with R-CHOP for patients with relapsed/refractory diffuse large B-cell lymphoma.

Recommendations for managing patients with diffuse large B-cell lymphoma on tafasitamab.

An overview of the LOTIS-1 clinical trial and the rationale for the accelerated approval of loncastuximab for relapsed/refractory diffuse large B-cell lymphoma.

Variables that are likely to impact the use of loncastuximab vs a combination approach with tafasitamab and lenalidomide to treat relapsed/refractory diffuse large B-cell lymphoma.

Recommendations to increase the uptake of CAR T-cell therapies into clinical practice when managing patients with relapsed/refractory diffuse large B-cell lymphoma.

Suggestions to hematologist-oncologists when talking to patients with relapsed/refractory diffuse large B-cell lymphoma about the potential benefits of CAR T-cell therapy and toxicities.

The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.